The Tesla Shock Nobody Sees Coming

While headlines scream "Tesla is doomed"...Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.

Nebius Vs. Palantir: The AI Infrastructure War At 100x Sales

Surbhi Jain
October 02, 2025

Wall Street's AI mania is minting new battlegrounds, and few look more intriguing than Nebius Group NV (NASDAQ:NBIS) versus Palantir Technologies Inc (NASDAQ:PLTR). Both stocks are commanding nosebleed valuations, each promising to dominate a different layer of the AI stack.

  • Track NBIS stock here.

The question for investors: does the real value sit in the physical backbone of AI, or in the applications that ride on top of it?

Infrastructure Vs. Applications

Nebius, spun out of Russian roots and now making its play in the U.S. markets, wants to become the ultimate infrastructure provider for the AI boom. Its model is straightforward -- build out massive GPU farms, expand data center capacity and secure energy supply to keep them humming.

In a world where NVIDIA Corp's (NASDAQ:NVDA) chips are scarce and every company from Meta Platforms Inc (NASDAQ:META) to OpenAI is fighting for compute power, Nebius is pitching itself as the indispensable supplier.

Read Also: Nebius Is Nvidia’s Strategic Weapon--And Microsoft Just Took The Bait

Palantir, by contrast, has long staked its claim as the "AI operating system" for enterprises and governments. Its Foundry and Gotham platforms are embedding AI into workflows -- defense intelligence, health care planning and industrial optimization.

If Nebius is selling shovels in the AI gold rush, Palantir wants to own the maps, the pans, and maybe the mining rights themselves.

Valuations At Altitude

The catch is price. According to Benzinga Pro data, Nebius trades at a price-to-sales ratio of 105.1, while Palantir sits even higher at 135.8. These are stratospheric multiples -- investors are effectively valuing both companies as if a century of growth will materialize in the next decade.

The market is assigning different risks to each. Nebius could benefit immediately from red-hot GPU demand, especially as hyperscalers scramble to secure compute power. Palantir, meanwhile, must prove that its AI deployments stick, expand, and become indispensable across industries.

Both stories are compelling -- but neither has room for execution missteps.

Investor Takeaway

The AI race is not just about chips or apps -- it's about which layer of the stack captures enduring value. Nebius is betting infrastructure scarcity will keep margins fat, while Palantir is banking on its role as the AI brain for enterprises.

At 100x sales, both stocks are priced for perfection. For investors, it may not be a matter of who wins big, but who blinks first.

Read Next:

  • Nvidia High-Fives Palantir, Rocket Lab -- On This List Of ’10-Bagger’ Legends

Photos: Courtesy Nebius; Palantir, Shutterstock

Continue Reading...

Popular

Trump administration cuts nearly $8B in clean energy projects in blue states

WASHINGTON (AP) — The Trump administration is cancelling $7.6 billion in grants that supported hundreds of clean energy projects in 16 states, all of which voted for Democrat Kamala Harris in last year's presidential election.

OpenAI's Deal Machine Is in Overdrive—From CoreWeave To UiPath And Walmart

OpenAI has accelerated its partnership engine dramatically and is reshaping the tech, enterprise and retail landscapes at a dizzying pace.

Elon's $25 Trillion Confession - Ad

Elon Musk: "Tesla will become a $25 trillion company." That would make Tesla 8x bigger than Apple today. How is that possible? He admits it's all thanks to this one AI breakthrough that will take AI out of our computer screens and manifest a 250x boom here in the real world.

Palantir Stock Climbs Nearly 2% In Thursday Pre-Market: What's Going On?

Shares of Palantir Technologies Inc. (NASDAQ: PLTR) climbed 1.53% in Thursday pre-market after it signed a strategic deal worth billions with the U.K. government.

Consumer Tech News (Sep. 15 – Sep. 19): Fed Rate Cut Lifts Wall Street To Records As Meta Unveils Smart Glasses, Nvidia-Intel Forge Chip Pact

Wall Street rallied to record highs after the Fed's rate cut, while Meta launched new smart glasses, Nvidia teamed with Intel on chips, and big names like General Mills, FedEx, and Darden reported earnings.

[Revealed] Trump's Next AI Executive Orders? - Ad

A White House insider with direct ties to Trump's inner circle just revealed what he calls "Manhattan II" - a potential $2.2 trillion AI initiative set to launch as soon as Oct 15. He says this could mirror past U.S. projects that minted fortunes - with small firms soaring 5,000% to 10,000% over two decades. And now he's giving away his #1 stock pick for free before the deadline.

Cathie Wood Dumps $5.2 Million Worth of This AI Stock, Here's What Ark Bought Instead

Ark Invest decided to sell shares of Tempus AI (TEM), despite positive news of FDA clearance for its diagnostic device. They also made other key trades.

Trump files $15 billion defamation lawsuit against The New York Times

NEW YORK (AP) — President Donald Trump filed a $15 billion defamation lawsuit against The New York Times and four of its journalists on Monday, according to court documents.

Biotech With Multiple Orphan Drugs Is Quietly Opening Its Doors - Ad

A promising biotech developing treatments for rare childhood brain diseases is opening a new raise. Its lead drug has fast-track status, orphan designations, is nearing Phase 2 and backed by a Global Integrator.

Cathie Wood's Ark Bets Big On Solana Treasury Play: Makes $162M Investment In Brera Holdings As Stock Explodes 225%

On Thursday, Cathie Wood-led Ark Invest executed significant trades, notably selling shares of Tempus AI Inc (NASDAQ:TEM) and buying shares of Brera Holdings PLC (NASDAQ:BREA),

New Biotech Offering Targets $426B Rare Disease Market - Ad

The rare disease drug space is growing fast-and so is investor interest. With exclusivity, pricing power and major M&A moves, the rare disease space is getting interesting. This company has the science and the experience.

Why was Jimmy Kimmel's late-night show suspended? Here's what we know

NEW YORK (AP) — ABC has pulled off the air, indefinitely — an unprecedented move that followed backlash from affiliated broadcasters and the head of the Federal Communications Commission over the comic's remarks about last week's killing of conservative activist .

It's 'do or die' for electric vehicle maker Rivian as it breaks ground on a $5 billion plant

ATLANTA (AP) — It seems like a terrible time to build an electric vehicle plant in the United States, but Rivian Automotive leaders say they're confident as the company starts on a $5 billion facility in Georgia.

The "Mar-A-Lago Accord" Is Now Underway - Ad

The global order is in chaos. And according to 40-year market veteran Dr. David Eifrig, the biggest controlled demolition of the old monetary order in history could now be here, too. That means if you don't take action today, your wealth could decline by 40%... (Yes, even your cash savings.)

AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial

AstraZeneca's Fasenra misses the primary COPD endpoint while Saphnelo's lupus trial shows significant improvements and consistent safety profiles.

Carney Cuts The Red Tape, Unveils Over $43 Billion In Flagship Projects

PM Mark Carney announces first projects to be reviewed by Canada's new Major Projects Office, aiming to cut red tape and attract investments.

Another Gold High? Here's the Move Wall Street Is Missing ... - Ad

Gold just surged past $3,600, up 45% in a year - but Sean Brodrick says $6,900 could be next. History shows when gold booms, one hidden play has delivered far bigger gains - 21x, 49x, even 1,386x. The same strategy once handed 26,000% profits. And Sean says it's back on the table now.

Johnson & Johnson's Tecvayli-Darzalex Combo Shows 100% Response In Newly Diagnosed Myeloma Patients

Johnson & Johnson's Tecvayli-Darzalex regimen showed 100% response rates and high MRD negativity in newly diagnosed multiple myeloma patients.

Trump's Immigration Policies Could 'Shrink' GDP Growth As US Population Projected To Decline, Warns CBO

The U.S. population growth is expected to decline at a faster rate than previously projected due to President Donald Trump's immigration policies, according to the Congressional Budget Office (CBO).

Rare Disease Biotech Offers Access Ahead of Key Milestone - Ad

This late-stage biotech is gearing up for Phase 2 trials with an FDA-designated orphan drug. It's already drawing comparisons to recent billion-dollar exits. Backed by a proven biotech incubator, it's now offering early access to its raise.

Lam Research And JSR Resolve Legal Disputes As They Team Up On AI Era Chips

Lam Research and JSR Corp agreed to collaborate and cross-license, combining their expertise to accelerate semiconductor manufacturing and reduce costs.

Gold Is Being Reintroduced Into the Monetary System - Ad

While the media focuses on political scandals, inflation and coming up with ridiculous acronyms "TACO"... Smart money is tracking a far bigger shift: a gold revaluation is quietly underway. Garrett Goggin, CFA, says this could trigger 100X moves in select miners - and he's identified four with the biggest upside.

US orders Delta and Aeromexico to dissolve their partnership over fairness concerns in Mexico

U.S. Transportation Secretary Sean Duffy is following through on to force Delta and Aeromexico to dissolve their longtime partnership because of his concerns that Mexico isn't being fair to U.S. airlines.

Cardlytics Stock Surges 5% After Hours As Citron Research Spotlights Wells Fargo Partnership

Cardlytics Inc. (NASDAQ: CDLX) saw its stock fall 9.85% during regular trading on Thursday. However, the stock rebounded in after-hours trading, climbing 5.04% to $2.50 following positive remarks from analysts.

Nvidia Is About to Shock the World: October 23rd - Ad

Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%, is warning everyone to... Mark this date on your calendar: October 23rd! That's when Nvidia could help send shares of this Elon Musk supplier skyrocketing higher.

Benzinga Bulls And Bears: Oracle, Micron, Land's End — And Ellison Briefly Bests Musk

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

The Tesla Shock Nobody Sees Coming - Ad

While headlines scream "Tesla is doomed"...Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.

In battles over free speech, comedians are often center stage

NEW YORK (AP) — Bassem Youssef, the Egyptian satirist whose after the military seized the once pro-democracy government, watched the suspension of Jimmy Kimmel with an immediate sense of familiarity.

Trump's $350 Billion Investment Demand Could Trigger 1997-Style Financial Crisis, Says South Korea's President

South Korean President Lee Jae Myung said that President Donald Trump's demands for a $350 billion investment in the U.S. could trigger a 1997-style Asian financial meltdown, without the necessary safeguards.

Elon's $25 Trillion Confession - Ad

Elon Musk: "Tesla will become a $25 trillion company." That would make Tesla 8x bigger than Apple today. How is that possible? He admits it's all thanks to this one AI breakthrough that will take AI out of our computer screens and manifest a 250x boom here in the real world.

Harvard Business School graduate arrested on charges he cheated fellow alums out of over $4 million

NEW YORK (AP) — A Harvard Business School graduate was arrested Thursday on fraud charges alleging he swindled fellow alumni of the prestigious school out of over $4 million in a Ponzi scheme, even assuring one investor they would soon “brag” about their “crazy gains” at the school's reunion.

Trump Hints TikTok Deal May Finally Be Complete But GOP China Hawks Demand ByteDance Disinvestment And Full Algorithm Split

President Donald Trump hinted that a TikTok deal may be near, but GOP lawmakers insist any agreement must enforce ByteDance's full divestment and an algorithm split from China.

[Revealed] Trump's Next AI Executive Orders? - Ad

A White House insider with direct ties to Trump's inner circle just revealed what he calls "Manhattan II" - a potential $2.2 trillion AI initiative set to launch as soon as Oct 15. He says this could mirror past U.S. projects that minted fortunes - with small firms soaring 5,000% to 10,000% over two decades. And now he's giving away his #1 stock pick for free before the deadline.

Elizabeth Warren Says Measles Can Hit Record Highs, Slams RFK Jr.'s CDC Panel For Delaying Vaccine: 'How Does That Keep Our Kids Safe?'

Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps, rubella, and varicella or MMRV vaccine for children under 4 years old.

Biotech With Multiple Orphan Drugs Is Quietly Opening Its Doors - Ad

A promising biotech developing treatments for rare childhood brain diseases is opening a new raise. Its lead drug has fast-track status, orphan designations, is nearing Phase 2 and backed by a Global Integrator.

Labor Dispute Eases As UAW, GE Aerospace Agree On Tentative Pact

UAW members at GE Aerospace plants in Ohio and Kentucky reached a tentative deal, with a ratification vote set for Sept. 19.

Trending Now

Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.

Copyright trendadvisor.net
Privacy Policy | Terms of Service